Roche sales down 5% as currency effects outweigh gains for haemophilia drug

Roche reported Q1 group revenues of 14.7 billion Swiss francs, in line with Visible Alpha estimates, with sales down 5% in reported terms but up 6% at constant exchange rates. The company reaffirmed full-year guidance for high-single-digit adjusted EPS growth and mid-single-digit sales growth, while key drugs Ocrevus, Hemlibra, and Xolair posted constant-currency sales gains of 6%, 13%, and 26%, respectively. Diagnostics remained pressured by China pricing reforms, with division sales down 7% reported but up 3% at constant currencies.

Analysis

Roche’s quarter reads as a quality check on defensiveness rather than a growth inflection: the core pharma portfolio is still compounding, but FX is doing real damage to reported growth and obscuring underlying operating leverage. The more important takeaway is that management is signaling the China diagnostics drag is moving from a acute shock to a normalization story; if that continues, the second-half setup for margins is better than headline sales suggests because the business is already operating through the comparison base.

The second-order effect is on sentiment across large-cap European healthcare: investors likely over-penalize any company with meaningful China diagnostics exposure or U.S. dollar revenue translation, even when underlying local-currency demand is intact. That creates a bifurcation trade between firms with genuine end-market weakness versus those with mostly translational noise; Roche looks closer to the latter, which should support multiple stability if the dollar stays soft and guidance is reiterated.

The contrarian angle is that the market may be underestimating how much of the current weakness is reversible within 1-2 quarters if FX stabilizes and China pricing comparisons ease. On the flip side, if the dollar strengthens again, reported growth will remain capped and the stock could stall despite improving fundamentals, so the catalyst path is less about absolute beats and more about whether management can string together a couple of clean constant-currency quarters.

For broader healthcare, the message is that large-cap pharma with resilient cash flows should screen better than diagnostics-heavy or device-heavy peers exposed to China pricing policy. That should keep relative support under quality mega-cap defensives versus more operationally leveraged medtech names until there is evidence the China reform overhang has fully cleared.

Key Decisions for Investors

• Go long ROOCH vs short a diagnostics-exposed peer basket for 1-2 quarters, betting that Roche’s China headwind becomes a fade rather than a structural margin reset; target 5-8% relative outperformance if FX stops worsening.
• Add to long Europe healthcare defensives on any post-earnings weakness, favoring large-cap pharma over diagnostics/medtech for the next 60-90 days; risk/reward is better because reported earnings can re-rate quickly if the dollar stabilizes.
• Short-term hedge: buy USDCHF downside protection only if you are long Roche or other Swiss exporters; the stock remains highly levered to translation, and a 2-3% further USD decline would likely pressure reported growth again this quarter.
• If you want an event-driven trade, wait for second-half guidance confirmation before adding size; the cleanest upside setup is a guidance reaffirmation plus sequential improvement in diagnostics, which could support a 3-5% move in the shares.
• Avoid chasing the quarter as a one-off beat; the better trade is a relative long in high-quality pharma against names with more operational China exposure, because the current market is still treating all healthcare slowdown the same.